Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Skeletal Muscle-derived Cell Implantation for the Treatment of Fecal Incontinence
NCT04976153Phase 3Recruiting
- Sponsor
- Innovacell
- Start
- May 2022
- Primary completion
- Dec 2027
- Modality
- Stem Cell Therapies
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in fecal incontinence (FI) comparing aSMDC with Placebo (2 arms). Primary endpoint: Changes in frequency of incontinence episodes at 12 months. Started May 2022; status: recruiting.
02
Drugs
ICEF 15
03
Conditions
fecal incontinence (FI)
Beyond the preview
Go deeper on NCT04976153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04976153.